- Price
- $508.34
- Day
- -1.55%
- Mkt Cap
- $129.02B
- 52W Range
- $374.17 – $560.25
- Volume
- 2.43M
- Beta
- 0.32
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $508.34, signifying a -1.55% move from its prior day's close.
Read full article
Nykredit A S purchased a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 204,386 shares of the pharmaceutical company's stock, valued at approximately $101,525,000. Nykredit A S owned 0.08% of Vertex Pharmaceuticals at
Read full article
Baird Financial Group Inc. decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 53.0% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,126 shares of the pharmaceutical company's stock after selling 4,645 shares during
Read full article
Engineers Gate Manager LP lowered its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 77.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,066 shares of the pharmaceutical company's stock after selling 10,752 shares during the period.
Read full article
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
Read full article
Amgen maintains a massive, diversified portfolio of medicines serving approximately 17 million patients globally. Vertex Pharmaceuticals dominates the cystic fibrosis market with exceptionally high net margins and a pristine balance sheet.
Read full article
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Read full article
Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.
Read full article
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Read full article
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Read full article
Vertex Pharmaceuticals' core business is rock-solid, but it is also slowly expanding into new areas. The company should see improved top-line growth over the next few years, driven by new launches.
Read full article
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read full article